Vaccines Archive

Vanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment

“These antibodies hold significant promise to be used in people who are at risk of measles, but who cannot respond to the measles vaccine due to their weakened immune systems,” said James Crowe Jr., MD, whose research team isolated the human monoclonal antibodies.

February 18, 2026

Novel vaccine protects against C. diff disease and recurrence

New study represents a major step forward for vaccine development for C. diff, the leading cause of health care- and antibiotic-associated infection.

By Leigh MacMillan

February 11, 2026

Vaccination cuts risk of COVID-19 respiratory failure or death by 80%

Researchers at Vanderbilt Health and around the country continue to evaluate the effectiveness of vaccines approved by the Food and Drug Administration to reduce the severity and lethality of respiratory infections caused by the ever-mutating SARS-CoV-2 virus.

December 15, 2025

Antibody research may lead to broadly protective flu vaccine

These findings could lead to the development of cross-reactive and neutralizing antibody therapies for individuals who are severely ill from the flu.

William Schaffner, MD. (photo by Erin O. Smith)

September 30, 2025

William Schaffner receives national honor for his vaccination, public health advocacy

The award honors medical school faculty members who have made major contributions to improving public health and health care.

(iStock)

Vanderbilt, Parse Biosciences scientists envision an antibody ‘atlas’ for measles, mumps, rubella

Researchers will scan the landscape of plasmablasts, the first antibody-producing, B-type immune cells that respond to MMR infection.

June 30, 2025

Coronavirus pioneer Mark Denison bids farewell to VUMC colleagues after remarkable career

The discoveries about coronavirus biology that Denison and his colleagues made were foundational for the rapid validation of antiviral drugs and development of new vaccines that helped bring the COVID-19 pandemic under control.

By Bill Snyder

December 11, 2024

Vanderbilt joins national effort to develop alphavirus vaccines

The project aims to design computational “tool kits” that can speed development of multi-virus vaccines targeting some of the greatest infectious threats to human health.

By Bill Snyder and Herschel Pollard

October 28, 2024

VUMC discovery aids effort to stop a deadly virus in Rwanda

A close cousin of Ebola, the Marburg virus is transmitted by fruit bats and by exposure to body fluids from infected individuals. There currently are no approved treatments or vaccines for MVD, which has a roughly 50% fatality rate.

By Bill Snyder

September 20, 2024

VUMC method tracks down rare, broadly reacting antibodies: study

The discovery, reported in the journal PLOS Pathogens, could help open the door to the development of effective vaccines and antibody therapies with an “exceptional breadth of pathogen coverage.”

By Bill Snyder

September 19, 2024

Fight the flu with Flulapalooza; annual event is set for Wed., Sept. 25; shots available at regional hospitals as well at other dates and times

Flulapalooza will happen at the tent between Light Hall and the VA Hospital from 6 a.m. – 6 p.m. Enter through Light Hall, North Lobby. Stop by to get your flu shot, reconnect with fellow colleagues, and interact with your favorite Nashville mascots.

September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.

By Bill Snyder

September 4, 2024

RSV vaccine in older people cuts risk of hospitalization

A multicenter study conducted in 19 states between October 2023 and March 2024 demonstrated that RSV vaccination was 75% effective in preventing RSV-associated hospitalizations for adults age 60 and older.

By Bill Snyder